Publication: BET bromodomain inhibition rescues erythropoietin differentiation of human erythroleukemia cell line UT7
Issued Date
2012-12-07
Resource Type
ISSN
10902104
0006291X
0006291X
Other identifier(s)
2-s2.0-84870388276
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Biochemical and Biophysical Research Communications. Vol.429, No.1-2 (2012), 1-5
Suggested Citation
Olivier Goupille, Tipparat Penglong, Carine Lefèvre, Marine Granger, Zahra Kadri, Suthat Fucharoen, Leila Maouche-Chrétien, Philippe Leboulch, Stany Chrétien BET bromodomain inhibition rescues erythropoietin differentiation of human erythroleukemia cell line UT7. Biochemical and Biophysical Research Communications. Vol.429, No.1-2 (2012), 1-5. doi:10.1016/j.bbrc.2012.10.112 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/13548
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
BET bromodomain inhibition rescues erythropoietin differentiation of human erythroleukemia cell line UT7
Abstract
Malignant transformation is a multistep process requiring oncogenic activation, promoting cellular proliferation, frequently coupled to inhibition of terminal differentiation. Consequently, forcing the reengagement of terminal differentiation of transformed cells coupled or not with an inhibition of their proliferation is a putative therapeutic approach to counteracting tumorigenicity. UT7 is a human leukemic cell line able to grow in the presence of IL3, GM-CSF and Epo. This cell line has been widely used to study Epo-R/Epo signaling pathways but is a poor model for erythroid differentiation. We used the BET bromodomain inhibition drug JQ1 to target gene expression, including that of c-Myc. We have shown that only 2. days of JQ1 treatment was required to transitory inhibit Epo-induced UT7 proliferation and to restore terminal erythroid differentiation. This study highlights the importance of a cellular erythroid cycle break mediated by c-Myc inhibition before initiation of the erythropoiesis program and describes a new model for BET bromodomain inhibitor drug application. © 2012 Elsevier Inc.